Stocktoria
NEPHROS INC NEPH
Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2004-09-21
NEPHROS INC statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 61.9% | 61.6% | 59.0% | 47.4% | 55.1% |
| Operating margin | 6.1% | 0.0% | -11.2% | -43.5% | -31.8% |
| Net margin | 6.4% | 0.5% | -11.1% | — | -37.8% |
| FCF margin | — | -3.9% | 5.3% | -33.8% | -14.2% |
| Return on assets | 8.8% | 0.7% | -13.3% | — | -21.9% |
| Return on equity | 11.7% | 0.9% | -18.8% | — | -26.2% |
| Debt / equity | — | — | — | 0.01× | 0.02× |
| Current ratio | 4.06 | 5.31 | 3.98 | 5.85 | 5.70 |
| Revenue growth | 32.7% | -0.5% | 42.7% | -2.4% | 19.3% |
Source: SEC EDGAR filings · CIK 0001196298 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.